Answers are grounded in this paper and cite their sources.
We found that the primary components of clinical evidence influencing NICE's decision-making framework were of poor quality. It is essential to continue to generate robust clinical data for premarket and postmarket introduction of medicines into clinical practice to ensure they deliver benefits to patients.
No takes yet. Share an insight, caveat, or question.
Osipenko et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: